ArticleBreast cancer research and treatment2025

Impact of extended endocrine therapy for patients with risk factors for late recurrence in estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after 5 years of endocrine therapy.

Masahiro Ito et al.PubMed ↗Publisher ↗

No numbers read from the abstract.